Your browser doesn't support javascript.
loading
CAR-based therapies: opportunities for immuno-medicine beyond cancer.
Aghajanian, Haig; Rurik, Joel G; Epstein, Jonathan A.
Afiliação
  • Aghajanian H; Department of Cell and Developmental Biology, Penn Cardiovascular Institute and Institute for Regenerative Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  • Rurik JG; Capstan Therapeutics, Philadelphia, PA, USA.
  • Epstein JA; Department of Cell and Developmental Biology, Penn Cardiovascular Institute and Institute for Regenerative Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Nat Metab ; 4(2): 163-169, 2022 02.
Article em En | MEDLINE | ID: mdl-35228742
ABSTRACT
One of the most exciting new therapies for cancer involves the use of autologous T cells that are engineered to recognize and destroy cancerous cells. Patients with previously untreatable B cell leukaemias and lymphomas have been cured, and efforts are underway to extend this success to other tumours. Here, we discuss recent studies and emerging research aimed to extend this approach beyond oncology in areas such as cardiometabolic disorders, autoimmunity, fibrosis and senescence. We also summarize new technologies that may help to reduce the cost and increase access to related forms of immunotherapy.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Antígenos Quiméricos / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Antígenos Quiméricos / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article